ArticleVirchows Archiv : an international journal of pathology2026
GLI1-fusion neoplasm of the tongue: report of a pediatric case associated with SHOX deficiency disorder.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GLI1-altered soft tissue tumor is a recently recognized entity featuring GLI1 fusions or amplifications, with predilection for the head and neck region and potential for metastasis. We report an additional case arising in the tongue of a 9-year-old boy with growth hormone insufficiency and epilepsy. Imaging showed an enhancing midline dorsal tongue lesion. Incisional biopsy revealed a multilobulated submucosal proliferation of monomorphic epithelioid-to-ovoid cells with prominent perivascular distribution around branching vessels and focal protrusion into vascular spaces. Tumor cells were GLUT-1 positive and negative for S100, GFAP, pan-cytokeratin, SMA, WT-1, CD31, CD34, STAT6, β-catenin, and HMB-45, with Ki-67 nuclear staining of 10-15% of cells. Next Generation Sequencing of the tumor confirmed ACTB::GLI1 fusion. In light of his neurodevelopmental disorders, further genetic evaluation was performed revealing SHOX deletion within PAR1 with complex Y-chromosomal rearrangement. Although GLI1-altered neoplasms have a distinctive morphology, lack of defining immunophenotype makes molecular confirmation of GLI1-altered soft tissue tumors essential in most cases. These tumors are low-grade sarcomas which are treated with complete local excision and long-term follow-up.
Indexed as
Identifiers
42159714What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.